MARC details
| 000 -LEADER |
|---|
| fixed length control field |
02478nam a22003257a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
170411s20162016 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
|---|
| International Standard Serial Number |
1751-2433 |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| PMID |
27367142 |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
Targeted therapies in thyroid cancer: an extensive review of the literature. |
| 251 ## - Source |
|---|
| Source |
Expert Review of Clinical Pharmacology. :1-15, 2016 Jul 15 |
| 252 ## - Abbreviated Source |
|---|
| Abbreviated source |
Expert Rev Clin Pharmacol. :1-15, 2016 Jul 15 |
| 253 ## - Journal Name |
|---|
| Journal name |
Expert review of clinical pharmacology |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Year |
2016 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Manufacturer |
FY2017 |
| 266 ## - Date added to catalog |
|---|
| Date added to catalog |
2017-05-24 |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
AREAS COVERED: Tyrosine Kinase Inhibitors (TKIs) have been studied extensively in TC: sorafenib and lenvatinib have been approved by the FDA for the treatment of metastatic, RAI-refractory DTC, while vandetanib and cabozantinib are FDA approved for use in advanced MTC. Moreover, several additional TKIs, multi-targeted or specific, are currently under investigation in TC. The current manuscript provides an extensive review of the literature regarding targeted therapies in TC including the rationale behind their use, the clinical trials and an expert opinion on their use. Literature in English appearing at PubMed was thoroughly reviewed, especially manuscripts of the last 5 years. Expert commentary: Patients with advanced, progressive, metastatic TC should be evaluated for enrollment in a clinical trial or should be placed on treatment with one of the FDA- and EMA- approved agents. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
INTRODUCTION: Patients with progressive, metastatic, RAI-refractory differentiated thyroid cancer (DTC), as well as patients with advanced medullary (MTC) and anaplastic thyroid cancer represent a cohort for which therapeutic options are limited. The recent discoveries in the molecular mechanisms implicated in TC have provided insight of the pathogenesis and progression of disease. In that respect, targeted therapies have emerged as a promising alternative for the treatment of those patients. |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
PubMed-not-MEDLINE -- Not indexed |
| 651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
|---|
| Institution |
MedStar Washington Hospital Center |
| 656 ## - INDEX TERM--OCCUPATION |
|---|
| Department |
Medicine/Endocrinology |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Journal Article |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Bikas, Athanasios |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Burman, Kenneth D |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Vachhani, Shivangi |
| 790 ## - Authors |
|---|
| All authors |
Bikas A, Burman KD, Jensen K, Vachhani S, Vasko V |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| DOI |
<a href="https://dx.doi.org/10.1080/17512433.2016.1204230">https://dx.doi.org/10.1080/17512433.2016.1204230</a> |
| Public note |
https://dx.doi.org/10.1080/17512433.2016.1204230 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Journal Article |
| Item type description |
Article |
